Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2026.1777196 Correction Correction: A differential process mining analysis of COVID-19 management for cancer patients CuendetMichel A. 1 2 3 Writing – original draft Writing – review & editing GattaRoberto 1 4 Writing – original draft Writing – review & editing WickyAlexandre 1 Writing – original draft Writing – review & editing GerardCamille L. 1 5 Dalla-ValeMargaux 1 Writing – original draft Writing – review & editing TavazziErica 6 Writing – original draft Writing – review & editing MichielinGrégoire 1 Writing – original draft Writing – review & editing DelyonJulie 1 Writing – original draft Writing – review & editing CesbronJulien 7 Writing – original draft Writing – review & editing LofekSébastien 7 Writing – review & editing Writing – original draft HuberAlexandre 7 Writing – original draft Writing – review & editing PradervandSylvain 1 Writing – original draft Writing – review & editing MichielinOlivier 1 2 * Writing – original draft Writing – review & editing Investigation Precision Oncology Center, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland Swiss Institute of Bioinformatics, Lausanne, Switzerland Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, United States Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy The Francis Crick Institute, London, United Kingdom Department of Information Engineering, University of Padova, Padova, Italy Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland Correspondence: Olivier Michielin, olivier.michielin@chuv.ch 02 03 2026 2026 16 1777196 29 12 2025 03 02 2026 14 01 2026 Copyright © 2026 Cuendet, Gatta, Wicky, Gerard, Dalla-Vale, Tavazzi, Michielin, Delyon, Cesbron, Lofek, Huber, Pradervand and Michielin. 2026 Cuendet, Gatta, Wicky, Gerard, Dalla-Vale, Tavazzi, Michielin, Delyon, Cesbron, Lofek, Huber, Pradervand and Michielin https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on A differential process mining analysis of COVID-19 management for cancer patients By Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S and Michielin O (2022) Front. Oncol. 12:1043675. doi: 10.3389/fonc.2022.1043675 process mining COVID-19 oncology process analysis clinical pathways section-at-acceptance Cancer Epidemiology and Prevention

Eight individuals listed as authors in the published article do not qualify for authorship and are no longer included. These are: Nabila Ferahta, Jeremy Jankovic, Rita Demicheli, Hasna Bouchaab, Antonia Digklia, Michel Obeid, Solange Peters, Manuela Eicher. The correct author list reads:

“Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Cesbron J, Lofek S, Huber A, Pradervand S and Michielin O.”

The Author Contributions Statement has been corrected to read:

“Clinical data collection: AW, MD-V, CG, GM, JD, JC, SL, AH. Methodological developments: MC, RG, AW, OM. Data analysis: MC, RG, AW, MD-V, CG, ET, SP, OM. Manuscript writing: MC, RG, CG”. All authors reviewed the article and approved the submitted version.

Following the withdrawal of authors, a correction has been made to the Acknowledgements.

“We acknowledge the medical teams that took care of the patients during the pandemic, in particular members of the Medical Oncology Division of CHUV.”

The Ethics statement was erroneously given as “The usage of retrospective patient data for this study was approved by the local Ethics Committee — Vaud Canton, Switzerland (Protocol No. 2019-00448). The patients/participants provided their written informed consent to participate in this study.” However, the reference to this protocol was unnecessary. The correct ethics statement is:

Ethics Statement

This study qualifies as a quality control study according to the Swiss Human Research Act, in which case usage of retrospective patient data is not subjected to ethics approval. We did not include data of patients who explicitly refused the CHUV general consent for health-related data re-use.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland